Table 1 Characteristics of control subjects and patients with Alzheimer's disease
Group | Age (years) | Sex | PMI (h) | Cause of death | Medications | Disease stage | Genotype |
|---|---|---|---|---|---|---|---|
Control | 60 | F | 21 | Cardiopulmonary attack | Aspirin | ApoE2/4/ ApoE2/3 | |
Control | 80 | M | 15 | Myocardial infarction | Furosemide | ApoE2/4 ApoE2/3 | |
Control | 79 | F | 19 | Cardiopulmonary attack | Isosorbide | ApoE2/4 ApoE2/3 | |
Control | 72 | M | 22 | Cardiopulmonary attack | Atorvastatin | ApoE2/4 ApoE2/3 | |
Control | 64 | M | 15 | Acute myocardial infarction | Vitamins | ApoE2/4 ApoE2/3 | |
Control | 74 | M | 18 | Cardiac arrest | Atenolol and digoxin | ApoE2/4 ApoE2/3 | |
Control | 61 | M | 22 | Myocardial infarction | Vitamins | ApoE2/4 ApoE2/3 | |
Control | 78 | F | 17 | Myocardial infarction | Atorvastatin | ApoE2/4 ApoE2/3 | |
Control | 63 | M | 15 | Heart failure | Furosemide | ApoE2/4 ApoE2/3 | |
Control | 71 | M | 23 | Cardiac arrest | Aspirin | ApoE2/4 ApoE2/3 | |
AD | 76 | F | 25 | Stroke | Sertraline, carbamazepine, alendronate and aspirin | V | ApoE4/4 |
AD | 83 | M | 17 | Stroke | Donepezil, valproate, tamsulosin and escitalopram | V | ApoE4/4 |
AD | 72 | M | 24 | AD | Atenolol, donepezil, valproate and alprazolam | VI | ApoE4/4 |
AD | 78 | F | 17 | AD | Fexofenadine, donepezil and aspirin | VI | ApoE4/4 |
AD | 75 | M | 15 | Atherosclerosis | Gabapentin, furosemide, quetiapine and escitalopram | VI | ApoE2/4 ApoE2/3 |
AD | 66 | M | 23 | Broken hip and AD | Rivastigmine and donepezil | V | ApoE2/4 ApoE2/3 |
AD | 63 | M | 18 | Pneumonia | Carbamazepine, sertraline, aspirin and quetiapine | VI | ApoE2/4 ApoE2/3 |
AD | 71 | M | 16 | End of AD | Atorvastatin, donepezil, pantoprazole, verapamil, vitamin E and risperidone | VI | ApoE2/4 ApoE2/3 |
AD | 61 | F | 21 | End of AD | Pantoprazole, verapamil, vitamin E and risperidone | VI | ApoE2/4 ApoE2/3 |
AD | 61 | M | 17 | Pneumonia | Valproate, quetiapine and olanzapine | VI | Not available |
